Substituted 1,3-thiazoles as heat shock transcription factor 1 activators
US-9447058-B2 · Sep 20, 2016 · US
Metabolism resistant fenfluramine analogs and methods of using the same
US2020331844A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2020331844-A1 |
| Application number | US-202016870128-A |
| Country | US |
| Kind code | A1 |
| Filing date | May 8, 2020 |
| Priority date | Dec 22, 2015 |
| Publication date | Oct 22, 2020 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.
First claim
Opening claim text (preview).
1 .- 11 . (canceled) 12 . A method of treating a refractory form of epilepsy, comprising: orally administering to a patient in need thereof a therapeutically effective amount of a metabolism-resistant fenfluramine analog having a structure selected from the group consisting of: 13 . The method of claim 12 , wherein the compound is which is (1,1-difluoroethyl)({1-[3-(trifluoromethyl)phenyl]propan-2-yl})amine. 14 . The method of claim 12 , wherein the method further comprises co-administering to the patient an antiepileptic agent.
Assignees
Inventors
Classifications
The ring being saturated · CPC title
with rings other than six-membered aromatic rings being part of the carbon skeleton · CPC title
with a four-membered ring · CPC title
Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title
- C07C211/29Primary
the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2020331844A1 cover?
- Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing th…
- Who is the assignee on this patent?
- Zogenix International Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07C211/29. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Oct 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).